» Articles » PMID: 24739649

Congenital Disorders of Glycosylation with Neonatal Presentation

Overview
Journal BMJ Case Rep
Specialty General Medicine
Date 2014 Apr 18
PMID 24739649
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital disorders of glycosylation (CDG) are a group of hereditary diseases characterised by deficiency of enzymes involved in proteins glycosylation. We describe the clinical case of a neonate with CDG type 1a, nowadays designated phosphomannomutase 2 (PMM2)-CDG. Physical examination showed an abnormal facies, axial hypotonia, abnormal fat distribution, inverted nipples, non-palpable testicles and arachnodactyly. Progressive multiple system organ involvement and worsening of hypertrophic cardiomyopathy occurred. Metabolic study revealed a CDG disturbance, which was confirmed by genetic study. The following mutations were identified: c.193G>T; p.D65Y and c.470T>C; p.F157S. Clinical deterioration was inevitable with multisystemic failure and death. CDG represents a challenge for physicians due to multiple organ involvement, and heterogeneous clinical manifestations. The neonatal form is usually associated with the worst prognosis.

Citing Articles

Motor improvement in children with PMM2-CDG syndrome following a six-month rehabilitation treatment utilising whole-body vibration; a retrospective study.

Bossier C, Stark C, Martakis K, Duran I, Schoenau E J Musculoskelet Neuronal Interact. 2024; 24(1):12-21.

PMID: 38427364 PMC: 10910202.


Metabolic Cardiomyopathies and Cardiac Defects in Inherited Disorders of Carbohydrate Metabolism: A Systematic Review.

Conte F, Sam J, Lefeber D, Passier R Int J Mol Sci. 2023; 24(10).

PMID: 37239976 PMC: 10218694. DOI: 10.3390/ijms24108632.


Fructose and Mannose in Inborn Errors of Metabolism and Cancer.

Lieu E, Kelekar N, Bhalla P, Kim J Metabolites. 2021; 11(8).

PMID: 34436420 PMC: 8397987. DOI: 10.3390/metabo11080479.


Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG).

Pettinato F, Mostile G, Battini R, Martinelli D, Madeo A, Biamino E Cerebellum. 2021; 20(4):596-605.

PMID: 33619652 PMC: 8360885. DOI: 10.1007/s12311-021-01242-x.


Cystic kidney diseases associated with mutations in phosphomannomutase 2 promotor: a large spectrum of phenotypes.

Dorval G, Jeanpierre C, Moriniere V, Tournant C, Bessieres B, Attie-Bittach T Pediatr Nephrol. 2021; 36(8):2361-2369.

PMID: 33580824 DOI: 10.1007/s00467-021-04953-9.


References
1.
Quelhas D, Quental R, Vilarinho L, Amorim A, Azevedo L . Congenital disorder of glycosylation type Ia: searching for the origin of common mutations in PMM2. Ann Hum Genet. 2006; 71(Pt 3):348-53. DOI: 10.1111/j.1469-1809.2006.00334.x. View

2.
Grunewald S . The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta. 2009; 1792(9):827-34. DOI: 10.1016/j.bbadis.2009.01.003. View

3.
Sharma V, Ichikawa M, He P, Scott D, Bravo Y, Dahl R . Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts. J Biol Chem. 2011; 286(45):39431-8. PMC: 3234766. DOI: 10.1074/jbc.M111.285502. View

4.
Noelle V, Knuepfer M, Pulzer F, Schuster V, Siekmeyer W, Matthijs G . Unusual presentation of congenital disorder of glycosylation type 1a: congenital persistent thrombocytopenia, hypertrophic cardiomyopathy and hydrops-like aspect due to marked peripheral oedema. Eur J Pediatr. 2005; 164(4):223-6. DOI: 10.1007/s00431-004-1611-x. View

5.
Clayton P, Winchester B, Keir G . Hypertrophic obstructive cardiomyopathy in a neonate with the carbohydrate-deficient glycoprotein syndrome. J Inherit Metab Dis. 1992; 15(6):857-61. DOI: 10.1007/BF01800221. View